Tirzepatide
FDA ApprovedAlso known as: Mounjaro, Zepbound
GLP-1/GIP Dual AgonistLast reviewed: April 28, 2026
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Mechanism of Action
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
Common Uses
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
Known Risks
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
Regulatory Status
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (Mounjaro/Zepbound)
Typical Dose
2.5 mg → 15 mg (titrated over 20 weeks)
Frequency
Once weekly
Cycle Length
Ongoing — not typically cycled
Start at 2.5 mg/week. Increase by 2.5 mg every 4 weeks as tolerated. Inject in abdomen, thigh, or upper arm.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.